Status:
COMPLETED
DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001
Lead Sponsor:
EyePoint Pharmaceuticals, Inc.
Conditions:
Cataract
Eligibility:
All Genders
18+ years
Brief Summary
Retrospective study to provide clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.
Detailed Description
This retrospective study is intended to provide large-scale, real-world data on clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Male and Female subjects at least 18 years of age
- Subjects who underwent cataract surgery from 12Mar2019 to 15Dec2019 and received DEXYCU
- Exclusion Criteria
- • Subjects who underwent cataract surgery and did not receive DEXYCU
Exclusion
Key Trial Info
Start Date :
November 13 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2020
Estimated Enrollment :
527 Patients enrolled
Trial Details
Trial ID
NCT04290676
Start Date
November 13 2019
End Date
May 1 2020
Last Update
May 26 2021
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Eye Center South Locations
Dothan, Alabama, United States, 36301
2
Inland Eye Specialists
Hemet, California, United States, 92545
3
Harvard Eye Associates
Laguna Hills, California, United States, 92653
4
Coastal Vision Medical Group
Orange, California, United States, 92868